The U.S. Food and Drug Administration has given full approval to baricitinib, a drug tested at UVA Health, as just the second drug to treat adults hospitalized with COVID-19.
The drug is intended for patients with severe cases of COVID-19, including patients requiring supplemental oxygen, ventilators or extracorporeal membrane oxygenation (ECMO).
Approval was based in large part on the results from the Adaptive COVID-19 Treatment Trial, or ACTT, which UVA Health participated in 2020 and 2021.
This page is available to subscribers. Click here to sign in or get access.